Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Biobetters Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the size of the biobetters market has seen swift expansion. Set to escalate from $67.81 billion in 2024 to $75.98 billion in 2025, it’s projected to have a compound annual growth rate (CAGR) of 12.0%. The remarkable growth observed in the historical period is predominantly due to better knowledge of disease mechanisms, a rise in healthcare spending, progress in manufacturing technology, innovation in medication delivery, advances in protein engineering, and a surge in the need for enhanced therapeutic effectiveness.
What Is the Forecast for the Biobetters Market Size Through 2029?
The size of the biobetters market is predicted to experience rapid expansion in the coming years, escalating to $118.2 billion by 2029 with a compound annual growth rate (CAGR) of 11.7%. Growth during this predictive period will be driven by factors such as advanced biotechnology, increasing focus on personalized medicine, the expansion of biopharmaceutical companies’ pipelines, rising instances of chronic diseases, regulatory advantages, increased funding in research and development, and progressive healthcare infrastructure. Key trends for this period will include the creation of new biobetters, protein engineering and rational design, concentration on therapy areas, an enhanced healthcare infrastructure, the progression of next-generation sequencing (NGS) technologies and improvements in high-throughput screening (HTS) technologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15522&type=smp
What are the Key Market Players in Biobetters Market and How They’re Evolving?
Major companies operating in the biobetters market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, F Hoffmann La Roche Ltd., Eli Lilly and Co Ltd., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., CSL Behring GmbH, Biogen Inc., GRIFOLS USA LLC, Celltrion Inc., Lonza Group AG, Ionis Pharmaceuticals Inc., Incyte Corporation, Amicus Therapeutics Inc., Genentech Inc., Sun Pharmaceutical Industries
What Are the Primary Growth Drivers in the Biobetters Market?
The biobetters market is expected to witness significant growth owing to the increasing cases of chronic kidney diseases. A chronic kidney disease is one that lasts for a prolonged period of time, gradually causing the kidneys to lose their ability to function correctly. The escalating numbers of this disease are due to an aging population, increased cases of diabetes and hypertension, unhealthy eating habits, lack of physical activity, pollution, and advanced diagnostic abilities. Biobetters contribute to managing chronic kidney disease by offering improved effectiveness, fewer side effects, optimal dosing schedules, and better stability as compared to the original biologic treatments, thus ensuring improved patient outcomes. As per Oxford Academic, UK’s academic research platform by Oxford University Press, the occurrence of CKD in the UK is predicted to surge by 4% – from 8.27 million to 8.61 million persons from 2022 till 2032, with different stages in 2032 as follows: 30.36% in stage 1, 21.07% in stage 2, 29.78% in stage 3a, 11.86% in stage 3b, 4.15% in stage 4, and 2.78% in stage 5. Thus, the rising incidence of chronic kidney diseases is fueling the expansion of the biobetters market. The growth of the biobetters market is also anticipated to be propelled by the growing cases of autoimmune diseases. Autoimmune conditions are those where the immune system mistakenly attacks the body’s healthy cells. The rise in these diseases can be attributed to factors like genetic susceptibility, environmental factors, and lifestyle alterations. Biobetters aid in combating autoimmune disorders by offering better efficacy, fewer side effects, superior dosing schedules, and enhanced stability, compared to the original biologic treatments, resulting in more effective management of these conditions. For instance, as per Public Health Scotland data, in 2022, cases of new patients diagnosed with multiple sclerosis (MS) rose to 87.2%, an increase from 85.7%, with 491 newly reported cases adding to the total of 6,359 in 2022. Furthermore, the Impact of IBD Report 2023 by the IBD Clinical and Research Centre, a Canada-based entity striving to enhance the lives of patients with Crohn’s and ulcerative colitis, suggests that the prevalence in 2023 is 825 per 100,000, with over 320,000 Canadians diagnosed with inflammatory bowel disease (IBD). And as the numbers are expected to rise by 2.44% annually, by 2035, around 1.1% of the population, or roughly 470,000 Canadians, could be living with IBD. Therefore, the increasing prevalence of autoimmune diseases is a significant driver for the growth of the biobetters market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15522&type=smp
What Are the Leading Segments in the Global Biobetters Industry?
The biobetters market covered in this report is segmented –
1) By Drug Class: Erythropoietin Biobetters, Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors, Interferon Biobetters, Insulin Biobetters, Monoclonal Antibodies Biobetters, Antihemophilic Factors, Other Drug Classes
2) By Route Of Administration: Oral, Subcutaneous, Inhaled, Intravenous, Other Routes
3) By Disease Indication: Diabetes, Cancer, Renal Disease, Neurodegenerative Diseases, Genetic Disorder-Hemophilia, Other Diseases
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Erythropoietin Biobetters: Darbepoetin Alfa, Continuous Erythropoietin Receptor Activator (CERA)
2) By Granulocyte-Colony Stimulating Factor (G-CSF) Biobetters: Pegfilgrastim, Lipegfilgrastim
3) By Interferon Biobetters: Pegylated Interferon Alfa-2a, Pegylated Interferon Alfa-2b
4) By Insulin Biobetters: Long-Acting Insulin Analogs (Insulin Glargine), Rapid-Acting Insulin Analogs (Insulin Aspart)
5) By Monoclonal Antibodies Biobetters: Trastuzumab (Herceptin Biosimilars), Bevacizumab (Avastin Biosimilars), Rituximab (Rituxan Biosimilars)
6) By Antihemophilic Factors: Recombinant Factor VIII (Nuwiq), Recombinant Factor IX (Alprolix)
7) By Other Drug Classes: Growth Factors, Cytokines, Enzyme Replacement Therapies, Vaccines
What Are the Key Market Trends in the Biobetters Industry?
Major corporations in the biobetters market are focusing on the development of biobetters for subcutaneous use to elevate the level of patient comfort, enhance the therapeutic effects, and lower the expense of healthcare. The subcutaneous application of biobetters presents a more user-friendly alternative to intravenous injections, potentially boosting patient adherence and the efficiency of healthcare delivery. For instance, Celltrion, a biopharmaceutical firm based in South Korea, received the green light from the Brazilian Health Regulatory Agency in May 2023 for their Remsima SC biobetters. This product, an advanced biobetter version of their infliximab biosimilar, Remsima, is the only infliximab in the world that can be administered subcutaneously. Remisma SC enhances a biosimilar, widening its accessibility and efficacy. It is particularly recommended for inflammatory bowel conditions such as Crohn’s disease and ulcerative colitis. It provides patients with a more manageable and potentially more beneficial treatment alternative.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/biobetters-global-market-report
What Is the Regional Outlook for the Biobetters Market?
North America was the largest region in the biobetters market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15522
This Report Delivers Insight On:
1. How big is the biobetters market, and how is it changing globally?
2. Who are the major companies in the biobetters market, and how are they performing?
3. What are the key opportunities and risks in the biobetters market right now?
4. Which products or customer segments are growing the most in the biobetters market?
5. What factors are helping or slowing down the growth of the biobetters market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
